Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30338333 | 1.00 | CYP1A2 (0.50) | CYP1A2CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL16482131 | 0.86 | IDO1 (0.49) | CYP1A2CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL9213137 | 0.81 | CYP1A2 (0.53) | CYP1A2CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL13579949 | 0.80 | NPC1 (0.57) | CYP1A2CYP2C19MAPTNPC1RAB9A | |
| SCHEMBL10163467 | 0.79 | RAB9A (0.49) | CYP1A2CYP2C19MAPTHTTNPC1 | |
| SCHEMBL22228506 | 0.79 | CYP1A2 (0.50) | CYP1A2CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL2624366 | 0.79 | SMN1; SMN2 (0.50) | CYP1A2CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL16199151 | 0.78 | NPC1 (0.47) | CYP1A2CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL2477370 | 0.78 | RAB9A (0.44) | CYP1A2CYP2C19MAPTCYP2D6CYP3A4 | |
| SCHEMBL3933042 | 0.78 | MAPT (0.50) | CYP1A2CYP2C19MAPTCYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368470-B2 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2008-05-06 | — | — | US | claimed |
| JP-2007501828-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1654253-B1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-01-03 | — | — | EP | claimed |
| EP-1654253-A1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2006-05-10 | — | — | EP | claimed |
| US-20050096376-A1 | Substituted 3-pyrrolidine-indole derivatives | GRUENENTHAL GMBH (DE) | 2005-05-05 | — | — | US | claimed |
| WO-2005019208-A1 | SUBSTITUTED 3-PYRROLIDIN-INDOLE DERIVATIVES | Grünenthal GmbH (DE) | 2005-03-03 | — | — | WO | claimed |
| US-6172261-B1 | BIOSYNTHESIS USING CHAIN EXTENSION | ORIDIGM CORPORATION | 2001-01-09 | — | — | US | claimed |
| EP-1001927-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 2000-05-24 | — | — | EP | claimed |
| WO-1999003823-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 1999-01-28 | — | — | WO | claimed |
| EP-3572402-B1 | LINKED CYCLIC COMPOUND AS CASPASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-05-04 | — | — | EP | disclosed |
| EP-3099668-B1 | 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2002064545-A1 | ACYLATED INDANYL AMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
| US-6369088-B2 | ANTIDIABETIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| EP-1085011-A1 | Novel polyamine analogues as therapeutic and diagnostic agents | ORIDIGM CORPORATION (US) | 2001-03-21 | — | — | EP | disclosed |
| US-6172261-B1 | BIOSYNTHESIS USING CHAIN EXTENSION | ORIDIGM CORPORATION | 2001-01-09 | — | — | US | disclosed |
| EP-1001927-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999003823-A2 | NOVEL POLYAMINE ANALOGUES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | ORIDIGM CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096376-A1 | Substituted 3-pyrrolidine-indole derivatives | OPRD1, OPRK1, TPH1 | CYP1A2 701/4885CYP2C19 760/4885MAPT 890/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | CYP1A2 3593/4885CYP2C19 4252/4885MAPT 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.